A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)
Withdrawn before enrolling · Phase 1
Conditions studied: Refractory Lupus Nephritis, Refractory Systemic Sclerosis
In brief
The main aim of the trial is to learn how well adults with refractory lupus nephritis (LN) or refractory systemic sclerosis (SSc) tolerate TAK-007 and to check for side effects (adverse events). Other aims are to learn how effective treatment with TAK-007 is in adults with refractory LN or refractory SSc, what effects TAK-007 has on the human body, and whether participants will produce antibodies against TAK-007.
Key facts
- Study ID
- NCT06377228
- Run by
- Takeda
- People needed
- 0
- Starts
- 2025-06-13
- Expected to finish
- 2030-09-02
- Last updated by the study team
- 2025-04-06
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas Health Science Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.